A biopharmaceutical company engaged in the discovery, development and commercialization of products that harness the human immune response to prevent and treat disease.


Updates from The Motley Fool

Latest updates on Celldex Therapeutics from Fool.com.  The Fool has written over 100 articles on Celldex Therapeutics.
The Worst Biotech Stocks of 2016

Many biotech stocks posted underwhelming performances in 2016. None, however, lost as badly as N...

3 Stocks That Could Make You Rich

Image source: Getty Images. Trying to get rich quick is a great way to lose a lot of money in the...



Stock Performance

View Interactive CLDX Charts
Sponsored by

Key Data Points

Primary metrics and data points about Celldex Therapeutics.
Current Price: $3.80
Prev Close: $3.95
Open: $3.86
Bid: $3.79
Ask: $3.80
Day's Range: $3.63 - $3.91
52wk Range: $2.85 - $16.65
Volume: 1,795,678
Avg Vol 2,716,111
Market Cap: $374M
P/E (ttm): -3.04
EPS (ttm): ($1.30)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Celldex Therapeutics.
CAPS Rating 4 out of 5
 
378 Outperform
18 Underperform
CAPS All Stars
 
61 Outperform
7 Underperform

How do you think Celldex Therapeutics will perform against the market?



You pick for Celldex Therapeutics is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Anthony S. Marucci, CEO

100% Approve

Based on 4 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Celldex Therapeutics.

A biopharmaceutical company engaged in the discovery, development and commercialization of products that harness the human immune response to prevent and treat disease.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers